ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VAL Valirx Plc

3.45
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.45 3.40 3.50 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -2.37M -0.0262 -1.32 3.11M
Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 3.45p. Over the last year, Valirx shares have traded in a share price range of 3.45p to 14.75p.

Valirx currently has 90,174,156 shares in issue. The market capitalisation of Valirx is £3.11 million. Valirx has a price to earnings ratio (PE ratio) of -1.32.

Valirx Share Discussion Threads

Showing 18776 to 18797 of 29350 messages
Chat Pages: Latest  754  753  752  751  750  749  748  747  746  745  744  743  Older
DateSubjectAuthorDiscuss
28/9/2020
08:32
https://twitter.com/dillysuzy/status/1310464007023845377?s=21
bloomberg2
28/9/2020
08:28
Our mkt cap is 35m..very different !! We have other opps as well
nico115
28/9/2020
08:25
I know, i know....feel gutted
stumbleupon
28/9/2020
08:20
Dr Suzy Dilly, Chief Executive Officer commented: "I am delighted to be able to share these exciting results today, which are an accumulation of a lot of work by the wider team, both within and external to ValiRx. While considering these results it is important to remember that this is only the first clinical trial using VAL201, so this data has been generated using the utmost caution in sequentially dosing patients. Nevertheless, the headline results clearly demonstrate that VAL201 has the potential to be a safe and well-tolerated drug. With this data in hand, future studies will investigate optimal dosing strategies for VAL201 and help confirm these early indications of a positive response rate."

Professor Alan Boyd, Consultant Pharmaceutical Physician and Medical Monitor for the study commented: "Development of effective treatments with low-side effects for patients with prostate cancer who have relapsed after radiotherapy is essential and will improve the lives of patients during treatment. I am pleased to have contributed to a project that has demonstrated such a good safety and tolerability profile while giving the first indications of a favourable effect on the patient's disease."

hope67
28/9/2020
08:18
Does anyone here remember British Biotech and its cancer drug marimastat?A sobering reminder of what can happen in phase three clinical trials.
steeplejack
28/9/2020
08:16
This is the real rise now the profit takers from last week are out... mad but hay ho.
Once the media get hold of these results £1 easy.

412069
28/9/2020
08:16
Am surprised we are not over 100p already on this huge news.54% is great result compared to most cancer drugs at such test stage
jungmana
28/9/2020
08:15
might just have had large holders selling into the news first thing, now the mm's make some money...
jusjusjus
28/9/2020
08:15
Just got in better late than never
bobaxe1
28/9/2020
08:15
One extremely happy holder here. Offers will come on from big pharmas for val201 soon.Amazingly cheap at GBP 36m market cap right now
jungmana
28/9/2020
08:14
People franticly buying back when they sold above 65
justtrying1
28/9/2020
08:14
Nt to sell at the rise,now nt to buy at the drop
arab3
28/9/2020
08:13
The Company intends to share these results with potential industry partners to evaluate all options for further clinical development of VAL201.

don't let yours go cheap

hope67
28/9/2020
08:09
Hmmmm. Works half the time, not dangerous, we hope to talk to some of the big players, proper results by end of year.

Maybe that’s good news in this industry, I hope so.

guss
28/9/2020
08:09
I think all the upside for VAL has happened in short term

Now the story is PYC who are TRIPLE WHAMMY winners

PYC haven't RNSed this yet

the stigologist
28/9/2020
08:08
Great results guys, obviously you will getting some sells now, but should be going higher later. All the best!
jassyb55
28/9/2020
08:08
Just the start!
wulber
28/9/2020
08:06
lotsa numpties taking their 10%...this has much further to rise
fez
28/9/2020
08:02
Managed to bag another 30k at 64.75p on open and expecting £1 today
tburns
28/9/2020
08:01
Well I got that wrong !!I thought 80p okie lol
nico115
28/9/2020
07:56
Yeah, you're right mally.

- I'm gonna sell the lot in five minutes, and put the lot into BT.

- or the 3:45 at Newton Abbot.

801710245
28/9/2020
07:56
NOTE

Physiomics earlier this year signed a deal with the No.1 Prostate Cancer drug seller Astellas (Xtandi (enzalutamide) which sells $3bn p.a.)

Could they be a bridge for VAL to approach Astellas with regard to partnering VAL201 with Xtandi ?

the stigologist
Chat Pages: Latest  754  753  752  751  750  749  748  747  746  745  744  743  Older

Your Recent History

Delayed Upgrade Clock